Fungal-Derived Fumagillin Emerges as Non-Surgical Treatment for Rare Corneal Infection

A major breakthrough has emerged in treating microsporidial stromal keratitis (MSK)—a rare and potentially blinding corneal infection caused by microsporidia, often linked to contaminated water exposure. Traditionally, severe cases required corneal transplantation. But recent research out of Hyderabad presents a promising non-surgical alternative using topical fumagillin—an antibiotic derived from fungus.

 

In a pilot study involving six eyes across five patients, physicians at the LV Prasad Eye Institute applied 0.007% fumagillin (with or without antifungal and antiparasitic medication) over nine months. All cases resolved without surgical intervention and remained relapse-free at one-year follow-up. Notably, even two complex cases—one involving corneal perforation, and another in an elderly patient managing glaucoma and cataracts—responded positively. Visual outcomes ranged from near-normal to moderate impairment.

Dr. Bhupesh Bagga emphasized the significance of this pilot study in reducing the need for invasive procedures and expressed optimism about fumagillin’s role in treating complex ocular infections.

Why This Matters for Eye Care

This development marks a pivotal shift in eye infection management:

• Avoids Invasive Surgery: Fumagillin offers a treatment option that avoids corneal transplantation, reducing risk and complexity.

• Non-Invasive Remedy: As a topical agent, fumagillin is a more patient-friendly option for serious corneal conditions.

• Broad Potential: Success in complex cases suggests potential applicability to other tough ocular infections if validated further.